Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01155089 · ClinicalTrials.gov registry record · NA
Bioequivalency Study of Anastrozole 1 mg Under Fed Conditions
A NA study, sponsored by Roxane Laboratories.
- Completed
- Registry status
- NA
- Development phase
- 32
- Enrollment target
NCT01155089: Completed NA study, sponsored by Roxane Laboratories.
NCT01155089 is a NA study that has completed, run by Roxane Laboratories. The registered enrollment target is 32 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01155089, a NA study, has completed, sponsored by Roxane Laboratories.
- COMPLETED
- Registry status
- NA
- Development phase
- 32 participants
- Enrollment target
Study Summary
The objective of this study was to prove the bioequivalence of Anastrozole Tablet under fed conditions
Interventions
- DRUG Anastrozole
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2006-05 |
| Est. Completion | 2006-06 |
| Phase | NA |
What the finished NCT01155089 record still lists
NCT01155089 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 32 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower).
The record links to 0 conditions, and to 1 intervention - of which Anastrozole is the first listed.
NCT01155089 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01155089 about?
NCT01155089 is a clinical study titled "Bioequivalency Study of Anastrozole 1 mg Under Fed Conditions". The objective of this study was to prove the bioequivalence of Anastrozole Tablet under fed conditions
What is the current status of trial NCT01155089?
This trial is currently completed. It is a NA study. The enrollment target is 32 participants. The study started on 2006-05. Estimated completion is 2006-06.
What interventions are being tested in trial NCT01155089?
The interventions under investigation include: Anastrozole (DRUG).
Who is sponsoring clinical trial NCT01155089?
This trial is sponsored by Roxane Laboratories, which has 93 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01155089's enrollment target sits among peer trials
32 1578th of 2000 higher than 409 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02445781 · 32 participants · Early Phase 1
Differing Levels of Hypoglycemia
- NCT02792270 · 32 participants · NA
Caloric Restriction In Sarcoma Patients Treated With Pre-Operative RT
- NCT03068910 · 32 participants · Early Phase 1
Hyperandrogenemia and Altered Day-night LH Pulse Patterns
- NCT03208868 · 32 participants · NA
Leucine Enriched Essential Amino Acid Mixture to Reverse Muscle Loss in Cirrhosis
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia